{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T22:49:45Z","timestamp":1791931785549,"version":"4.3.4"},"reference-count":18,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2013,8,29]],"date-time":"2013-08-29T00:00:00Z","timestamp":1377734400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2014,3]]},"abstract":"<jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To evaluate the efficacy and safety of initial combination therapy of sitagliptin 100\u2009mg\/day coadministered with all marketed doses of pioglitazone in patients with type 2 diabetes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Patients with\n                      <jats:styled-content style=\"fixed-case\">A1c<\/jats:styled-content>\n                      \u22657.5 and \u226411.0% were randomized among seven arms that received, once daily, 100\u2009mg sitagliptin alone; 15, 30 or 45\u2009mg pioglitazone alone, or 100\u2009mg sitagliptin plus 15, 30 or 45\u2009mg pioglitazone for 54\u2009weeks. The primary endpoint was change from baseline in\n                      <jats:styled-content style=\"fixed-case\">A1c<\/jats:styled-content>\n                      at week 24. Protocol\u2010specified analyses compared combination therapies with monotherapies at respective dose\u2010strengths and combination of sitagliptin plus pioglitazone 30\u2009mg with pioglitazone 45\u2009mg monotherapy.\n                      <jats:italic>Post\u2010hoc<\/jats:italic>\n                      analyses compared sitagliptin plus pioglitazone 15\u2009mg with pioglitazone monotherapy at the two higher doses.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Initial combination therapy with sitagliptin and pioglitazone provided significantly greater reductions in\n                      <jats:styled-content style=\"fixed-case\">A1c<\/jats:styled-content>\n                      (0.4\u20130.7% differences) and other glycaemic endpoints than either monotherapy at the same doses. Combining sitagliptin with low\u2010dose pioglitazone generally produced greater glycaemic improvements than higher doses of pioglitazone monotherapy (0.3\u20130.4% differences in\n                      <jats:styled-content style=\"fixed-case\">A1c<\/jats:styled-content>\n                      ). Combination therapy was generally well tolerated; adverse events (\n                      <jats:styled-content style=\"fixed-case\">AEs<\/jats:styled-content>\n                      ) of hypoglycaemia were reported with similar incidence (7.8\u201311.1%) in all treatment groups over the 54\u2009weeks of study; oedema was reported in 0.5% of patients in the sitagliptin monotherapy group and 2.7\u20135.3% among pioglitazone\u2010treated groups. Significant weight gain was observed in all combination\u2010treated groups compared with the sitagliptin monotherapy group.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Initial combination therapy with sitagliptin and pioglitazone provided better glycaemic control than either monotherapy and was generally well tolerated.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.12194","type":"journal-article","created":{"date-parts":[[2013,8,2]],"date-time":"2013-08-02T13:52:12Z","timestamp":1375451532000},"page":"223-230","source":"Crossref","is-referenced-by-count":32,"title":["Efficacy and safety of initial combination treatment with sitagliptin and pioglitazone\u2014a factorial study"],"prefix":"10.1111","volume":"16","author":[{"given":"R. R.","family":"Henry","sequence":"first","affiliation":[{"name":"Center for Metabolic Research, VA San Diego Healthcare System San Diego CA USA"},{"name":"University of California San Diego San Diego CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Staels","sequence":"additional","affiliation":[{"name":"UMR1011 Inserm University Lille Nord de France, Institut Pasteur de Lille Lille Cedex France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V. A.","family":"Fonseca","sequence":"additional","affiliation":[{"name":"Tulane University Health Sciences Center New Orleans LA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Z.","family":"Chou","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc. Whitehouse Station NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Teng","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc. Whitehouse Station NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. T.","family":"Golm","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc. Whitehouse Station NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. B.","family":"Langdon","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc. Whitehouse Station NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. D.","family":"Kaufman","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc. Whitehouse Station NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Steinberg","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc. Whitehouse Station NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. J.","family":"Goldstein","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc. Whitehouse Station NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,8,29]]},"reference":[{"key":"e_1_2_8_2_1","unstructured":"American Association of Clinical Endocrinologist (AACE) Guidelines. American Association of Clinical Endocrinologists. Available from URL:http:\/\/www.aace.com\/publications\/guidelines. Accessed 19 September 2012."},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-0413"},{"key":"e_1_2_8_4_1","unstructured":"Canadian Diabetes Association 2008 Clinical Practice Guidelines. Canadian Diabetes Association. Available from URL:http:\/\/www.diabetes.ca\/for\u2010professionals\/resources\/2008\u2010cpg\/. Accessed 19 September 2012."},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-1297"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/fampra\/cmp053"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2006.00698.x"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-0159"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2011.01391.x"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2010.02589.x"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740331003623218"},{"key":"e_1_2_8_12_1","unstructured":"FDA Drug Safety Communication (2010): Ongoing Safety Review of Actos (pioglitazone) and Potential Increased Risk of Bladder Cancer After Two Years Exposure. FDA Web site. Available from URL:http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm226214.htm. Updated 22 September 2010. Accessed 23 January 2012."},{"key":"e_1_2_8_13_1","doi-asserted-by":"crossref","unstructured":"Bortolini M Wright MB Bopst M Balas B. Examining the safety of PPAR agonists \u2010 current trends and future prospects. Expert Opin Drug Saf2013;12:65\u201379.","DOI":"10.1517\/14740338.2013.741585"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2012.03.001"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc06-0703"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00280883"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2006.10.007"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-031526"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1753-0407.2012.00223.x"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdom.12194","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.12194","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:18:02Z","timestamp":1761869882000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.12194"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,29]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["10.1111\/dom.12194"],"URL":"https:\/\/doi.org\/10.1111\/dom.12194","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,29]]}}}